» Articles » PMID: 8984942

Further Validation of the BILAG Disease Activity Index in Patients with Systemic Lupus Erythematosus

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 1996 Oct 1
PMID 8984942
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the association among the BILAG disease activity index components and their relations with global assessments, health status, and laboratory tests with regard to the validity of the BILAG index.

Methods: A cross sectional study of consecutive patients with systemic lupus erythematosus (SLE) attending a specialist lupus outpatient clinic between July 1994 and February 1995. The internal consistency of the British Isles Lupus Assessment Group (BILAG) index-a disease activity assessment system for SLE patients, based on the principle of the physician's intention to treat-was examined using Cronbach's coefficient alpha. The association of the components of the BILAG index with health status as measured with the MOS Short Form 20 (SF-20), with patients' and doctors' global assessments of patient wellbeing and with laboratory tests was analysed with Spearman rank correlations.

Results: 133 female and eight male patients, age 20.1 to 88.7 years (mean 41.1, SD 12.5), were included. With few exceptions, the components of the BILAG index which reflect disease activity in different organ systems were not associated with each other. With the exception of the mucocutaneous component, we found a significant relation between all components of BILAG and global assessment of patient wellbeing, health status, erythrocyte sedimentation rate, or serum C3 level.

Conclusions: The study confirms the validity of all but the mucocutaneous component of the BILAG index. However, disease activity in different organ systems in SLE does not follow a common pattern. Thus the individual BILAG components should be used rather than the total BILAG score as a primary endpoint in clinical and epidemiological studies. To capture the total effect of SLE on an individual measures of disease activity, damage, and health status are all needed.

Citing Articles

Serum Levels of T Cell Immunoglobulin and Mucin-Domain Containing Molecule 3 in Patients with Systemic Lupus Erythematosus.

Asano T, Matsuoka N, Fujita Y, Matsumoto H, Temmoku J, Yashiro-Furuya M J Clin Med. 2020; 9(11).

PMID: 33167436 PMC: 7694535. DOI: 10.3390/jcm9113563.


Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.

Ugarte-Gil M, Gamboa-Cardenas R, Reategui-Sokolova C, Pimentel-Quiroz V, Zena-Huancas P, Elera-Fitzcarrald C Lupus Sci Med. 2020; 7(1).

PMID: 33046557 PMC: 7552838. DOI: 10.1136/lupus-2020-000419.


Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus.

Matsuoka N, Fujita Y, Temmoku J, Furuya M, Asano T, Sato S PLoS One. 2020; 15(1):e0227069.

PMID: 31986153 PMC: 6984724. DOI: 10.1371/journal.pone.0227069.


Top 10 things to know about lupus activity measures.

Thanou A, Merrill J Curr Rheumatol Rep. 2013; 15(6):334.

PMID: 23606072 DOI: 10.1007/s11926-013-0334-2.


Belimumab in systemic lupus erythematosus: an update for clinicians.

Kim S, Kirou K, Erkan D Ther Adv Chronic Dis. 2012; 3(1):11-23.

PMID: 23251765 PMC: 3513897. DOI: 10.1177/2040622311424806.


References
1.
Lloyd W, Schur P . Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore). 1981; 60(3):208-17. DOI: 10.1097/00005792-198105000-00004. View

2.
Morrow W, Isenberg D, Todd-Pokropek A, Parry H, Snaith M . Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med. 1982; 51(202):125-38. View

3.
Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

4.
Stewart A, Hays R, Ware Jr J . The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988; 26(7):724-35. DOI: 10.1097/00005650-198807000-00007. View

5.
Karlson E, Daltroy L, Lew R, Wright E, Partridge A, Roberts W . The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum. 1995; 38(2):267-73. DOI: 10.1002/art.1780380217. View